Hiv-1 neutralizing antibodies and uses thereof
AssigneeInstitute for Research In Bioscience
InventorsAntonio Lanzavecchia, Davide Corti
Life of this patent
Estimating the term…
Abstract
The invention relates to antibodies and antigen binding fragments thereof that neutralize HIV-1 infection. The invention also relates to nucleic acids that encode, immortalized B cells and cultured plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of HIV-1 infection.
Claims25
An antibody, or an antigen binding fragment thereof, comprising at least one complementarity determining region (CDR) sequence having at least 95% sequence identity to any one of SEQ ID NOs:
- 17-22, 1-6, or 33-38, wherein the antibody or antigen binding fragment neutralizes HIV-1 infection.
An antibody, or an antigen binding fragment thereof, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 29 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 30;
- or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 13 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 14;
- or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 45 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 46, wherein the antibody or antigen binding fragment neutralizes HIV-1 infection.
Dependencies are inferred from the claim text.